甲胺通过阻断STAT3乙化,通过减少乙-CoA的生产,减轻结肠炎
Xiangyun Li1, Zixuan Xiang1, Xiaoli Wang2
1Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China; Key Laboratory of Hubei Province for Digestive System Disease, Wuhan, Hubei Province, China; Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
Journal of advanced research
|April 2, 2025
概括
甲福明通过抑制STAT3乙化,一种依赖于乙-CoA的过程来减少大肠炎的炎症. 这一发现揭示了性结肠炎治疗的新治疗点.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 甲胺可以缓解小鼠的硫酸 (DSS) 诱导的大肠炎.
- 甲福明在结肠炎中的抗炎和屏障修复作用的机制尚未完全理解.
研究的目的:
- 调查乙辅酶A (乙-CoA) 依赖STAT3乙化在甲胺治疗作用中的作用.
- 确定性结肠炎 (UC) 治疗的新型分子标.
主要方法:
- 在C57BL/6J小鼠中诱导的急性结肠炎使用了DSS并用甲胺治疗.
- 评估了肠道炎症,屏障完整性和通过组织病理学,西部涂抹和电子显微镜的STAT3信号.
- 利用特定于肠表皮的STAT3敲击小鼠来确认STAT3在结肠炎中的作用和甲胺的作用.
主要成果:
- 甲福明抑制了促炎性细胞因子和上皮细胞亡,恢复了紧密结合蛋白.
- 甲胺降低了乙-CoA水平,抑制了STAT3乙化和下游信号.
- 在STAT3淘汰的小鼠中,甲福明的治疗效果减弱,证实了STAT3的关键作用.
结论:
- 乙-CoA依赖的STAT3乙化是一种用于甲福林治疗大肠炎的新机制.
- 这些发现有助于更好地了解甲胺的免疫调节特性.
- 向乙-CoA代谢是一种潜在的治疗策略,用于性结肠炎.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
110
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
110
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
109
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
109
Oral Hypoglycemic Agents: Biguanides and Glitazones
143
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
143
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
128
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
128
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
91
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
91
Dipeptidyl Peptidase 4 Inhibitors
140
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
140


